ClinicalTrials.gg
Status unknownNCT00577304Updated Feb 5, 2010

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

A Phase 3 interventional study of Nitroglycerin and Topical AmphiMatrix in Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma and Raynaud's Disease Secondary to Other Autoimmune Disease, sponsored by MediQuest Therapeutics. Status unknown at 17 sites in United States. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-05.

Sponsored by MediQuest Therapeutics · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2008), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.

Planned enrollment
2nd of 33
200 · median 34
Started
2007
with 2 others
Phase 3
7 of 33
none open now
Registered
9th of 33
by date
Lead sponsor
8 of 33
MediQuest Therapeutics

Among the 33 studies in Raynaud Disease with a site in United States, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 9th registered.

Raynaud Disease

81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.

Browse Raynaud Disease studies →

Open to participants now

2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Raynaud Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Read the detailed description

The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's Phenomenon (RP) and with moderate to severe Raynaud's Phenomenon secondary to autoimmune diseases, such as scleroderma.

03

Conditions studied

  • Raynaud's Disease
  • Raynaud's Disease Secondary to Scleroderma
  • Raynaud's Disease Secondary to Other Autoimmune Disease

Keywords

  • Raynaud's
  • Nitroglycerin
  • Scleroderma
04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients ages 15 - 70.
  • Patients with a diagnosis of Raynaud's phenomenon.
  • Patients who agree to apply study medication to their fingers.
  • Patients who are willing to stop current topical vasodilator therapies.
  • Patients who agree not to start or change dosage of current oral vasodilator therapies.
  • Patients who agree not to use any nitrate therapy while participating in this study.
  • Negative pregnancy test in fertile women and agreement to use effective throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who currently use nitrate medication or medications known to interact with nitroglycerin.
  • Patients who have an allergy to nitroglycerin or common topical gel ingredients.
  • Patients with a history of severe headaches.
  • Patients with an unstable medical problem.
  • Patients with cognitive or language difficulties that would impair their ability to complete assessment of pain instruments.
  • Patients who have had a recent heart attack or other uncontrolled heart condition.
  • Patients who have participated in an drug study within four weeks of visit one.
  • Patients who have abnormal lab values.
  • Patients who have had recent major abdominal, thoracic or vascular surgery.
  • Patients with interfering skin conditions.
  • Pregnant or nursing women or women unwilling to comply with requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Other
    2

    Placebo - Topical AmphiMatrix

    Drug: Topical AmphiMatrix

  • Active comparator
    1

    Topical AmphiMatrix with Nitroglycerin

    Drug: Nitroglycerin

Interventions

  • Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

  • DrugTopical AmphiMatrix

    Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

06

What researchers measure

Primary outcomes

  1. Reduction in Raynaud's Condition Score

    Time frame: three months

Secondary outcomes

  1. Frequency and severity of adverse events.

    Time frame: three months

07

Study locations

17 sites
  • Stanford University
    Stanford, California 94305, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80045, United States
  • University of Connecticut
    Farmington, Connecticut 06030, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins University
    Baltimore, Maryland 21224, United States
  • Boston University
    Boston, Massachusetts 02118, United States
  • Arthritis Education and Treatment Center, PLLC
    Grand Rapids, Michigan 49546, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Medicine and Dentistry of New Jersey
    New Brunswick, New Jersey 08093, United States
  • The Center for Rheumatology
    Albany, New York 12206, United States
  • SUNY Stony Brook
    Stony Brook, New York 11794, United States
  • Carolina Arthritis
    Wilmington, North Carolina 28401, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas at Houston
    Houston, Texas 77030, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2007
First posted
Dec 20, 2007
Start
Dec 2007
Primary completionEst.
Mar 2008
CompletionEst.
Mar 2008
Last update
Feb 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00577304
Lead sponsor
MediQuest Therapeutics
First posted
Dec 20, 2007
Start date
Dec 2007
Primary completion
Mar 2008 (estimated)
Completion
Mar 2008 (estimated)
Last update
Feb 5, 2010

Study contacts

Jan Ohrstrom, PhD
study director · MediQuest Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion